lung cancer; small cell lung cancer; treatment Abstract: Lung cancer was relatively uncommon at the turn of the 20th century, and has increased in prevalence at alarming rates, particularly because of the augmented trend in smoking, so that it is now the most common cause of cancer death in...
Small Cell Lung Cancer Small cell lung cancer(SCLC) is a rapidly proliferating, biologically aggressive form of lung cancer that has a short survival without treatment.61These tumors probably arise from neuroendocrine cells, which contain neurosecretory granules, and may secretepeptide hormones.14...
Although small cell lung cancer (SCLC) is treated as a homogeneous disease, biopsies and preclinical models reveal heterogeneity in transcriptomes and morphology. SCLC subtypes were recently defined by neuroendocrine transcription factor (NETF) expressio
Non-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is responsible for the majority of cancer-related deaths worldwide. The management of NSCLC has improved considerably, especially in the past 10 years. The systematic screeni
Small-cell lung cancer (SCLC), an aggressive neuroendocrine tumor with early dissemination and dismal prognosis, accounts for 15–20% of lung cancer cases and∼200,000 deaths each year. Most cases are inoperable, and biopsies to investigate SCLC biology are rarely obtainable. Circulating tumor c...
The advent of PD-(L)1 and CTLA-4 immune check point inhibitors (CPIs) has dramatically changed the treatment landscape of advanced non-small-cell lung cancer (NSCLC). For up to a quarter of patients with advanced NSCLC, CPIs have the potential to induce durable r...
NHS: National health system NMR: Nuclear magnetic resonance NSCLC: Non-small cell lung cancer OS: Overall survival PET: Positron emission tomography PFS: Progression-free survival SBRT: Stereotactic body radiotherapy SEER: Surveillance, epidemiology, and end results SEOM: Spanish Society of...
(brigatinib) as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor. ALUNBRIG is a next-generation tyrosine kinase inhibitor (TKI) that was designed to target...
Non-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is responsible for the majority of cancer-related deaths worldwide. The management of NSCLC has improved considerably, especially in the past 10 years. The systematic screeni
Lung cancer Epidermal growth factor receptor Resistance Drug development 1. Introduction Activating mutations in the Epidermal Growth Factor Receptor (EGFR) are the most common targetable oncogenic driver mutation in metastatic non-small cell lung cancer (NSCLC). There has been significant change in the...